Skip to main content
OMER
NASDAQ Life Sciences

Omeros Q3: YARTEMLEA Sales $35.9M, Net Loss $57.4M on Non-Cash Derivative Mark

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$14.996
Mkt Cap
$1.207B
52W Low
$6.59
52W High
$21.24
52W Position info
128% above low
Off High info
29% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

OMER has more than doubled off its 52-week low of $6.59.

Summary

Omeros' Q3 loss of $57.4 million was driven by a $62.0 million non-cash derivative remeasurement, while YARTEMLEA sales grew 26% sequentially to $35.9 million and the company generated $13.3 million of quarterly operating cash flow.


Key Events · Earnings and Guidance · OMER

  • YARTEMLEA Sales Grow 26% Sequentially

    Q3 net product sales were $35.9 million versus $28.5 million in Q2 (a $7.4 million, 26.0% increase), with 109 unique ordering accounts by September 30, up 49% since June 30.

  • Loss Driven by Non-Cash Derivative Mark

    The $57.4 million net loss includes a $62.0 million non-cash loss on remeasurement of the 2029 Notes embedded derivative and repurchase obligation as the stock price rose — no cash outflow and no change in share count.

  • Operating Cash Flow Turns Positive

    Cash provided by operations was $13.3 million for Q3 and $2.9 million for the nine months, versus $76.3 million used in the prior-year nine-month period; cash and short-term investments totaled $95.3 million at September 30.

  • EU Approval Path Effectively Closed

    CHMP upheld its negative opinion on narsoplimab for TA-TMA on October 16, 2026 after re-examination, so Omeros does not expect EU marketing authorization on the current MAA.


Analysis · OMER · Life Sciences

The headline $57.4 million quarterly loss is almost entirely a non-cash accounting swing: a $62.0 million mark-to-market loss on the 2029 Notes conversion derivative as the stock rose, not a cash outflow and not new dilution. The operating story is better than the bottom line suggests — YARTEMLEA net sales reached $35.9 million, up 26.0% from Q2, with 109 ordering accounts (a 49% increase since June 30), and the company generated $13.3 million of cash from operations in the quarter. Cash and investments of $95.3 million plus commercial sales are expected to fund more than 12 months of operations. The offsetting negatives: the EU path for narsoplimab is effectively closed after CHMP upheld its negative opinion on October 16, and SG&A is climbing as the commercial build-out continues.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OMER was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.59 to $21.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OMER - Latest Insights

OMER
Nov 16, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $17.53
Real-time Price: $15.79 info
Change: -$1.74 (-10%) info
Market Cap: $1.207B info
OMER
Oct 16, 2026, 6:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.05
Real-time Price: $15.79 info
Change: -$1.26 (-7%) info
Market Cap: $1.207B info
OMER
Aug 12, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.11
Real-time Price: $15.79 info
Change: -$0.320 (-2%) info
Market Cap: $1.207B info
OMER
Aug 12, 2026, 4:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $15.60
Real-time Price: $15.79 info
Change: +$0.190 (+1%) info
Market Cap: $1.207B info
OMER
Aug 03, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $12.00
Real-time Price: $15.79 info
Change: +$3.79 (+32%) info
Market Cap: $1.207B info